NCT04773522: Phase 1 - JNJ-64407564 in Japanese Participants With Relapsed or Refractory Myeloma
Updated: Sep 29, 2022
Phase 1
Relapsed & Refractory Myeloma
A Study of JNJ-64407564 in Japanese Participants With Relapsed or Refractory Multiple Myeloma
The purpose of this study is to evaluate the safety and tolerability in Japanese participants with relapsed or refractory multiple myeloma (MM) at the recommended Phase 2 dose (RP2D) identified in NCT03399799 study.
JNJ-64407564
Talquetamab
Sponsor
ClinicalTrials.gov Identifier: NCT04773522
Official Title: A Phase 1 Study of JNJ-64407564, a Humanized GPRC5D * CD3 Bispecific Antibody in Japanese Subjects With Relapsed or Refractory Multiple Myeloma
First Posted : February 26, 2021
Click here to see details on ClinicalTrials.gov
Location
Japan
RELATED POSTS
TECLISTAMAB STUDIES:
NCT03145181: Phase 1 - Teclistamab, Humanized BCMA*CD3 Bispecific Ab, in Relapsed Myeloma (MajesTEC1)
NCT04557098: Phase 2- Teclistamab, in Participants With Relapsed or Refractory Myeloma (MajesTEC-1)
NCT05083169: Phase 3 - Tec-Dara Vs DPd Vs DVd in Relapsed or Refractory Myeloma - (MajesTEC-3)
NCT05243797: Phase 3: Tec + Len Vs Len Alone in NDMM as Maintenance Therapy Post ASCT (MajesTEC-4)
NCT04722146: Phase 1b - Teclistamab With Other Anticancer Therapies in Participants With Myeloma
NCT05231629: Phase 2: Sequential Therapy in Multiple Myeloma Guided by MRD Assessments (MASTER-2)
TALQUETAMAB STUDIES:
NCT03399799: Phase 1 - Talquetamab, a Humanized GPRC5D x CD3 Bis Ab - Ref MM - MonumenTAL-1
NCT04634552: Phase 2 - A Study of Talquetamab in Participants With Refractory Multiple Myeloma
NCT05050097: Phase 1 - A Study of Talquetamab With Other Anticancer Therapies in Multiple Myeloma
TECLISTAMAB AND TALQUETAMAB STUDIES:
NCT04586426: Phase 1b - Talquetamab and Teclistamab in Relapsed or Refractory Multiple Myeloma
NCT04108195: Phase 1b - Subcutaneous Dara With Bispecific T Cell Redirection Antibodies - TRIMM-2